原薬(API)の世界市場2016-2022

Stratistics MRCが発行した調査報告書(SMRC70207007)
◆英語タイトル:Active Pharmaceutical Ingredients - Global Market Outlook (2016-2022)
◆商品コード:SMRC70207007
◆発行会社(リサーチ会社):Stratistics MRC
◆発行日:2017年1月
◆ページ数:176
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥468,950見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算¥593,250見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Stratistics MRC社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、原薬(API)の世界市場について調査・分析し、原薬(API)の世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
- エグゼクティブサマリー
- 序文
- 原薬(API)の世界市場:市場動向分析
- 原薬(API)の世界市場:競争要因分析
- 原薬の世界市場:原薬種類別
・合成化学原薬
・バイオ原薬
・高活性原薬(HPAPI)
- 原薬の世界市場:製造種類別
・自家用製造
・委託製造
- 原薬の世界市場:治療用途別
・抗感染薬
・心臓血管・造血系
・中枢神経系・神経疾患
・糖尿病
・内分泌学
・消化器疾患
・ホルモン障害
・代謝異常
・筋骨格障害
・腎臓
・腫瘍学
・眼科
・整形外科的障害
・肺臓学
- 原薬(API)の世界市場:主要地域別分析
- 原薬(API)の北米市場規模(アメリカ市場等)
- 原薬(API)のヨーロッパ市場規模
- 原薬(API)のアジア市場規模(日本市場、中国市場、インド市場等)
・原薬(API)の世界市場:主な市場開拓
- 関連企業分析
【レポートの概要】

According to Stratistics MRC, the Global Active Pharmaceutical Ingredients market is expected to grow from $129.12 billion in 2015 to reach $198.8 billion by 2022 with a CAGR of 6.4%. Patent expiration of prominent drugs, government initiatives, regional penetration and increasing aged population are some of the factors that are driving the market growth. Strict validation and safety guidelines stated by WHO and fragmented market are the factors that are hampering the API market growth.

Generic/Non- Branded segment witnessed the largest market share during the forecast period due to rising healthcare costs, government prominence on generics for dropping healthcare costs, and decreasing pipelines of global pharmaceutical products. Asia Pacific is expected to be highest market share during the forecast period due to low operation costs and high investments in medical research. Moreover, the high cost of skilled labour and energy are the most significant factors that enforced European market to move its base to developing countries, such as India and China.

Some of the key players in global Active Pharmaceutical Ingredients market include Bioniche Animal Health (Canada), Boehringer Ingelheim (Germany), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Bayer Healthcare (Germany), Merial Inc. (Sanofi) (France), Elanco Animal Health (U.S.), Merck Animal Health (U.S.), Ceva Animal Health, Inc., Dr. Reddy’s Laboratories Ltd., Novartis International AG, Ranbaxy Laboratories, Virbac, Zoetis (U.S.), Pfizer, Inc, Aurobindo Pharma Ltd., and Heska Co. (U.S.)

Types of API Covered:
• Synthetic chemical API
o Branded/ Innovative
o Generic/Non- Branded
• Biological API
o Biotech
o Biosimilar
• High potency active pharmaceutical ingredients(HPAPI)
Types of Manufacturing Covered:
• Captive (or in-house) manufacturing
• Contract manufacturing

Therapeutic Applications Covered:
• Anti-Infectives
• Cardiovascular and hematopoietic system
• CNS and Neurological Disorders
• Diabetes
• Endocrinology
• Gastrointestinal disorder
• Hormonal-related disorder
• Metabolic disorder
• Musculoskeletal disorder
• Nephrology
• Oncology
• Ophthalmology
• Orthopedic Disorders
• Pulmonology
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Active Pharmaceutical Ingredients Market, By Types of API
5.1 Introduction
5.2 Synthetic chemical API
5.2.1 Branded/ Innovative
5.2.2 Generic/Non- Branded
5.3 Biological API
5.3.1 Biotech
5.3.2 Biosimilar
5.4 High potency active pharmaceutical ingredients(HPAPI)

6 Global Active Pharmaceutical Ingredients Market, By Type of Manufacturing
6.1 Introduction
6.2 Captive (or in-house) manufacturing
6.3 Contract manufacturing

7 Global Active Pharmaceutical Ingredients Market, By Therapeutic Application
7.1 Introduction
7.2 Anti-Infectives
7.3 Cardiovascular and hematopoietic system
7.4 CNS and Neurological Disorders
7.5 Diabetes
7.6 Endocrinology
7.7 Gastrointestinal disorder
7.8 Hormonal-related disorder
7.9 Metabolic disorder
7.10 Musculoskeletal disorder
7.11 Nephrology
7.12 Oncology
7.13 Ophthalmology
7.14 Orthopedic Disorders
7.15 Pulmonology

8 Global Active Pharmaceutical Ingredients Market, By Geography
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 UK
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Australia
8.3.5 New Zealand
8.3.6 Rest of Asia Pacific
8.4 Rest of the World
8.4.1 Middle East
8.4.2 Brazil
8.4.3 Argentina
8.4.4 South Africa
8.4.5 Egypt

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Bioniche Animal Health (Canada)
10.2 Boehringer Ingelheim (Germany)
10.3 Sun Pharmaceutical Industries Ltd.
10.4 Teva Pharmaceutical Industries Limited
10.5 Bayer Healthcare (Germany)
10.6 Merial Inc. (Sanofi) (France)
10.7 Elanco Animal Health (U.S.)
10.8 Merck Animal Health (U.S.)
10.9 Ceva Animal Health, Inc.
10.10 Dr. Reddy’s Laboratories Ltd.
10.11 Novartis International AG
10.12 Ranbaxy Laboratories
10.13 Virbac
10.14 Zoetis (U.S.)
10.15 Pfizer, Inc
10.16 Aurobindo Pharma Ltd.
10.17 Heska Co. (U.S.)

List of Tables
Table 1 Global Active Pharmaceutical Ingredients Market Outlook, By Region (2013-2022) ($MN)
Table 2 Global Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
Table 3 Global Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
Table 4 Global Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
Table 5 Global Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
Table 6 Global Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
Table 7 Global Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
Table 8 Global Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
Table 9 Global Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
Table 10 Global Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
Table 11 Global Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
Table 12 Global Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
Table 13 Global Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
Table 14 Global Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
Table 15 Global Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
Table 16 Global Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
Table 17 Global Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
Table 18 Global Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
Table 19 Global Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
Table 20 Global Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
Table 21 Global Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
Table 22 Global Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
Table 23 Global Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
Table 24 Global Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
Table 25 Global Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
Table 26 Global Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
Table 27 Global Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
Table 28 North America Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
Table 29 North America Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
Table 30 North America Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
Table 31 North America Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
Table 32 North America Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
Table 33 North America Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
Table 34 North America Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
Table 35 North America Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
Table 36 North America Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
Table 37 North America Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
Table 38 North America Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
Table 39 North America Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
Table 40 North America Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
Table 41 North America Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
Table 42 North America Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
Table 43 North America Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
Table 44 North America Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
Table 45 North America Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
Table 46 North America Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
Table 47 North America Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
Table 48 North America Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
Table 49 North America Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
Table 50 North America Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
Table 51 North America Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
Table 52 North America Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
Table 53 North America Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
Table 54 North America Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
Table 55 Europe Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
Table 56 Europe Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
Table 57 Europe Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
Table 58 Europe Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
Table 59 Europe Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
Table 60 Europe Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
Table 61 Europe Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
Table 62 Europe Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
Table 63 Europe Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
Table 64 Europe Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
Table 65 Europe Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
Table 66 Europe Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
Table 67 Europe Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
Table 68 Europe Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
Table 69 Europe Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
Table 70 Europe Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
Table 71 Europe Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
Table 72 Europe Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
Table 73 Europe Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
Table 74 Europe Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
Table 75 Europe Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
Table 76 Europe Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
Table 77 Europe Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
Table 78 Europe Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
Table 79 Europe Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
Table 80 Europe Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
Table 81 Europe Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
Table 82 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
Table 83 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
Table 84 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
Table 85 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
Table 86 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
Table 87 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
Table 88 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
Table 89 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
Table 90 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
Table 91 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
Table 92 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
Table 93 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
Table 94 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
Table 95 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
Table 96 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
Table 97 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
Table 98 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
Table 99 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
Table 100 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
Table 101 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
Table 102 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
Table 103 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
Table 104 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
Table 105 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
Table 106 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
Table 107 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
Table 108 Asia Pacific Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)
Table 109 RoW Active Pharmaceutical Ingredients Market Outlook, By Country (2013-2022) ($MN)
Table 110 RoW Active Pharmaceutical Ingredients Market Outlook, By Types of API (2013-2022) ($MN)
Table 111 RoW Active Pharmaceutical Ingredients Market Outlook, By Synthetic chemical API (2013-2022) ($MN)
Table 112 RoW Active Pharmaceutical Ingredients Market Outlook, By Branded/ Innovative (2013-2022) ($MN)
Table 113 RoW Active Pharmaceutical Ingredients Market Outlook, By Generic/Non- Branded (2013-2022) ($MN)
Table 114 RoW Active Pharmaceutical Ingredients Market Outlook, By Biological API (2013-2022) ($MN)
Table 115 RoW Active Pharmaceutical Ingredients Market Outlook, By Biotech (2013-2022) ($MN)
Table 116 RoW Active Pharmaceutical Ingredients Market Outlook, By Biosimilar (2013-2022) ($MN)
Table 117 RoW Active Pharmaceutical Ingredients Market Outlook, By High potency active pharmaceutical ingredients(HPAPI) (2013-2022) ($MN)
Table 118 RoW Active Pharmaceutical Ingredients Market Outlook, By Type of manufacturing (2013-2022) ($MN)
Table 119 RoW Active Pharmaceutical Ingredients Market Outlook, By Captive (or in-house) manufacturing (2013-2022) ($MN)
Table 120 RoW Active Pharmaceutical Ingredients Market Outlook, By Contract manufacturing (2013-2022) ($MN)
Table 121 RoW Active Pharmaceutical Ingredients Market Outlook, By Therapeutic applications (2013-2022) ($MN)
Table 122 RoW Active Pharmaceutical Ingredients Market Outlook, By Anti-Infectives (2013-2022) ($MN)
Table 123 RoW Active Pharmaceutical Ingredients Market Outlook, By Cardiovascular and hematopoietic system (2013-2022) ($MN)
Table 124 RoW Active Pharmaceutical Ingredients Market Outlook, By CNS and Neurological Disorders (2013-2022) ($MN)
Table 125 RoW Active Pharmaceutical Ingredients Market Outlook, By Diabetes (2013-2022) ($MN)
Table 126 RoW Active Pharmaceutical Ingredients Market Outlook, By Endocrinology (2013-2022) ($MN)
Table 127 RoW Active Pharmaceutical Ingredients Market Outlook, By Gastrointestinal disorder (2013-2022) ($MN)
Table 128 RoW Active Pharmaceutical Ingredients Market Outlook, By Hormonal-related disorder (2013-2022) ($MN)
Table 129 RoW Active Pharmaceutical Ingredients Market Outlook, By Metabolic disorder (2013-2022) ($MN)
Table 130 RoW Active Pharmaceutical Ingredients Market Outlook, By Musculoskeletal disorder (2013-2022) ($MN)
Table 131 RoW Active Pharmaceutical Ingredients Market Outlook, By Nephrology (2013-2022) ($MN)
Table 132 RoW Active Pharmaceutical Ingredients Market Outlook, By Oncology (2013-2022) ($MN)
Table 133 RoW Active Pharmaceutical Ingredients Market Outlook, By Ophthalmology (2013-2022) ($MN)
Table 134 RoW Active Pharmaceutical Ingredients Market Outlook, By Orthopedic Disorders (2013-2022) ($MN)
Table 135 RoW Active Pharmaceutical Ingredients Market Outlook, By Pulmonology (2013-2022) ($MN)



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 原薬(API)の世界市場2016-2022(Active Pharmaceutical Ingredients - Global Market Outlook (2016-2022))]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆